

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF NEW JERSEY**

IN RE SELENIOUS ACID LITIGATION	C.A. No. 2:24-cv-7791-BRM-CLW (consolidated)
AMERICAN REGENT, INC. v. SOMERSET THERAPEUTICS, LLC et al	C.A. No. 2:24-cv-07807-BRM-CLW
AMERICAN REGENT, INC. v. SOMERSET THERAPEUTICS, LLC et al	C.A. No. 2:24-cv-11124-BRM-CLW
AMERICAN REGENT, INC. v. SOMERSET THERAPEUTICS, LLC et al	C.A. No. 2:24-cv-11138-BRM-CLW

**CONSENT JUDGMENT**

American Regent, Inc. (“ARP”), and Somerset Therapeutics, LLC, Somerset Pharma, LLC, and Odin Pharmaceuticals, LLC (collectively, “SOMERSET”), parties in the above-captioned Actions, specifically in the Actions initiated by Plaintiff, ARI, against SOMERSET in Civil Action No. 2:24-07807-BRM-CLW, have resolved these litigations for good cause and valuable consideration recognized by ARI and SOMERSET. Now the parties, by their respective undersigned attorneys, hereby stipulate and consent to entry of judgment and an injunction in the Actions, as follows:

IT IS this 19<sup>th</sup> day of March, 2025:

ORDERED, ADJUDGED AND DECREED as follows:

1. This District Court has jurisdiction over the subject matter of the above Actions and has personal jurisdiction over the parties.
2. As used in this Consent Judgment, (i) the term “SOMERSET Product(s)” shall mean the drug product(s) manufactured, sold, offered for sale or distributed pursuant to Abbreviated New Drug Application No. 218780 (including any supplements, or modifications, or

amendments thereto or replacements thereof) (“SOMERSET’s ANDA”); (ii) the term “Licensed ARI Patents” shall mean United States Patent No. 11,998,565 (“the ‘565 patent”) and United States Patent No. 12,150,957 (“the ‘957 patent”); and (iii) the term “Affiliate” shall mean any entity or person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with SOMERSET; for purposes of this definition, “control” means: (a) ownership, directly or through one or more intermediaries, of: (1) more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or (2) more than fifty percent (50%) of the equity interests in the case of any other type of legal entity or status as a general partner in any partnership; or (b) any other arrangement whereby an entity or person has the right to elect a majority of the Board of Directors or equivalent governing body of a corporation or other entity or the right to direct the management and policies of a corporation or other entity.

3. Unless otherwise specifically authorized by ARI or by 35 U.S.C. § 271(e)(1), SOMERSET, including any of its Affiliates, successors and assigns, is enjoined from infringing the Licensed ARI Patents, on its own part or through any Affiliate, by making, having made, using, selling, offering to sell, importing, or distributing of the SOMERSET Product(s) in the United States.

4. Compliance with this Consent Judgment may be enforced by ARI, its successors in interest, or assigns, as permitted by the terms of the Settlement Agreement.

5. This District Court retains jurisdiction to enforce or supervise performance under this Consent Judgment.

6. All claims, counterclaims, affirmative defenses and demands in these Actions are hereby dismissed without prejudice and without costs, disbursements or attorneys' fees to any party, except as otherwise agreed to by the parties.

7. Nothing herein shall preclude the U.S. Food & Drug Administration from granting final approval to SOMERSET's ANDA or shall preclude SOMERSET from filing, modifying, or maintaining with the FDA any Paragraph IV Certification for the SOMERSET Product(s) pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV).



Brian R. Martinotti  
United States District Judge

We hereby consent to the form and entry of this Order:

s/ Charles H. Chevalier

Charles H. Chevalier  
GIBBONS P.C.  
One Gateway Center  
Newark, New Jersey 07102-5310  
(973) 596-4611  
cchevailier@gibbonslaw.com

Christine A. Gaddis  
GIBBONS P.C.  
141 West Front Street, Suite 240  
Red Bank, New Jersey 07701  
(732) 704-5801  
cgaddis@gibbonslaw.com

OF COUNSEL:

Dennies Varughese, Pharm. D.  
Uma Everet  
Adam LaRock  
Alex Alfano  
Ryan Conkin

s/ James S. Richter

James S. Richter  
MIDLIGE RICHTER, LLC  
645 Martinsville Road  
Basking Ridge, New Jersey 07920  
(908) 626-0622

Of Counsel:

Kurt Mathas  
Kevin Boyle  
WINSTON & STRAWN LLP  
35 W. Wacker Dr.  
Chicago, Illinois 60601  
Tel. (312) 558-5600  
kmathas@winston.com  
kboyle@winsoton.com

Claire Fundakowski  
Lauren Rennecker  
WINSTON & STRAWN LLP  
1901 K Street, N.W.

Sterne, Kessler, Goldstein & Fox  
P.L.L.C.  
1101 K Street, NW, 10th Floor  
Washington, DC 20005  
(202) 371-2600  
dvarughese@sternekessler.com  
ueverett@sternekessler.com  
alarock@sternekessler.com  
aalfano@sternekessler.com  
rconkin@sternekessler.com

*Attorneys for Plaintiff American  
Regent, Inc.*

Washington, DC 20036  
Tel. (202) 282-5000  
cfundakowski@winston.com  
lrennecker@winston.com

*Attorneys for Defendants Somerset Therapeutics,  
LLC, Somerset Pharma, LLC, and Odin  
Pharmaceuticals, LLC*